Compare Cassava Sciences Inc (FLNA) vs IQIYI Inc - ADR (IQ) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Cassava Sciences Inc vs IQIYI Inc - ADR — how do they compare? Cassava Sciences Inc trades at $1.07 (market cap $53.14M), while IQIYI Inc - ADR trades at $1.23 (market cap $1.15B). The key difference: IQIYI Inc - ADR is far larger — about 21.6× Cassava Sciences Inc's market cap, and IQIYI Inc - ADR is trading nearer its 52-week high, Cassava Sciences Inc nearer its low. Which is the better fit depends on your goals.
| FLNA | IQ | |
|---|---|---|
Market Cap | $53.14M | $1.15B |
Sector | Health | Media |
52-Week High | $4.64 | $2.79 |
52-Week Low | $1.09 | $0.96 |
Enterprise Value | -$33.43M | $2.71B |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Filana Therapeutics (FLNA) trades at $1.09, down 5.22% on the day, reflecting persistent operational losses despite recent earnings beats. The stock exhibits a strong bearish technical signal, with moving averages and oscillators aligned negatively. Fundamentally, the company is in a pre-revenue biotech development phase, evidenced by significant negative cash flow from operations (-$32.25M in 2025) and deeply negative profitability metrics (ROE: -79.59%). Recent news highlights continued focus on its Tuberous Sclerosis Complex (TSC)-related epilepsy program.
The outlook is bifurcated: a bullish analyst consensus (8 Buy, 4 Hold, 0 Sell) suggests optimism for the clinical pipeline, while severe financial burn and bearish technicals present substantial near-term risk. Investment opportunity hinges entirely on successful drug development, with significant dilution or financing risk as the company funds operations. The stock is suitable only for high-risk investors comfortable with binary clinical outcomes.
IQ (iQIYI) trades at $1.16, up 2.65% today, with a bullish technical signal from moving averages but a neutral oscillator stance. The company reported a net loss of $206.31 million in 2025, with revenue declining to $27.29 billion, though it beat EPS expectations in two of the last three quarters. Recent news highlights AI platform growth and leadership changes as potential turnaround catalysts.
The outlook is mixed: analyst consensus leans buy (50%) with price predictions citing upside potential, but profitability challenges and revenue declines pose risks. Investment opportunity hinges on AI-driven content innovation offsetting competitive pressures in China's streaming market.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Cassava Sciences Inc
Cassava Sciences Inc is a clinical-stage biotechnology company engaged in developing a scientific approach for the treatment and detection of Alzheimer's disease. Its therapeutic product candidate is called simufilam, and it is a novel treatment for Alzheimer's disease
Read more on FLNA →About IQIYI Inc - ADR
iQIYI Inc is an online entertainment service provider in China. It is primarily engaged in providing a variety of services encompassing internet video, live broadcasting, online games, online literature, animations, e-commerce, and social media platform. The company produces original video content and distributes appealing professionally produced content, partner-generated content, and user-generated content. It also offers a diverse collection of internet video content that appeals to users from broad demographics. The company's revenue is generated from membership services and online advertising services. The company earns most of its revenue from China.
Read more on IQ →
